See the DrugPatentWatch profile for Akynzeo
Akynzeo, a combination therapy for chemotherapy-induced nausea and vomiting (CINV), has undergone clinical trials to assess its efficacy and safety [1][2]. These trials have been crucial in establishing its role in managing acute and delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy [2][3].
How effective is Akynzeo in preventing CINV?
Clinical studies have demonstrated that Akynzeo, in combination with a corticosteroid like dexamethasone, provides a high rate of complete response in patients receiving chemotherapy [2][4]. A complete response is generally defined as no nausea and no use of rescue medication [2]. Trials have shown that this combination therapy can achieve complete control of nausea and vomiting in a significant majority of patients across different chemotherapy regimens [2][3][4].
What are the key components of Akynzeo?
Akynzeo is a fixed-dose combination of netupitant, a neurokinin-1 (NK1) receptor antagonist, and palonosetron, a 5-HT3 receptor antagonist [1][2]. This dual mechanism targets two critical pathways involved in the nausea and vomiting reflex [1]. Netupitant blocks the action of substance P on NK1 receptors, while palonosetron blocks serotonin on 5-HT3 receptors [1].
How does Akynzeo compare to older antiemetic regimens?
Akynzeo offers an advantage over older regimens by providing a more comprehensive blockade of CINV pathways [1][5]. Traditional antiemetic approaches often relied solely on 5-HT3 antagonists or relied on multi-drug regimens with potentially more complex administration [5]. The combination in Akynzeo addresses both acute (within 24 hours) and delayed (24-120 hours) phases of CINV more effectively due to the distinct pharmacodynamic profiles of its components [2][3].
What is the typical dosage and administration for Akynzeo?
Akynzeo is administered orally as a single capsule approximately one hour before the start of chemotherapy [1][3]. The recommended dose is 300 mg of netupitant and 0.5 mg of palonosetron [1].
What side effects have been reported in Akynzeo clinical trials?
Commonly reported side effects in clinical trials for Akynzeo are generally mild to moderate and can include constipation, fatigue, headache, and indigestion [1][3]. Serious adverse events are rare [3]. The safety profile is considered favorable, particularly when compared to the significant distress caused by uncontrolled CINV [2][3].
When does Akynzeo's patent protection expire?
Information regarding the specific patent expiration dates for Akynzeo and its components can be found through drug patent tracking resources [6]. For detailed patent timelines and exclusivity periods, DrugPatentWatch.com provides comprehensive data [6].
Who manufactures Akynzeo?
Akynzeo is developed and marketed by Helsinn [1].
*
**Sources:
[1] https://www.drugpatentwatch.com/drugs/akynzeo
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4440253/
[3] https://www.nejm.org/doi/full/10.1056/NEJMoa1314257
[4] https://pubmed.ncbi.nlm.nih.gov/24804202/
[5] https://www.cancernetwork.com/view/netupitant-palonosetron-akynzeo-for-chemotherapy-induced-nausea-and-vomiting
[6] https://www.drugpatentwatch.com/